Spyre Therapeutics, Inc. SYRE

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.

Our goal is to develop next-generation therapeutics to redefine the standard of care for the treatment of IBD and other immune-mediated diseases, relying on three strategic pillars:

•Advancing a portfolio of next-generation monotherapies - novel antibody candidates engineered for optimized potency, selectivity, and pharmacokinetics ("PK") against validated IBD targets

Last close 90.33 2026-10-23
Market cap $7.96B 2026-06-30 share count
52-week range 21.14 - 110.17

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $0$0$886.0K$2.3M$18.7M$0$0$3.9M$5.2M$4.6M
R&D ———$58.6M$57.1M$59.6M$64.6M$36.7M$22.8M$18.1M
SG&A $47.9M$45.8M$39.9M$28.5M$27.3M$21.8M$15.7M$12.6M$10.1M$8.4M
Total operating expenses $209.6M$208.6M$243.2M$87.1M$84.4M$81.5M$80.3M$49.4M$32.9M$26.5M
Operating income -$209.6M-$208.6M-$242.3M-$84.8M-$65.6M-$81.5M-$80.3M-$45.5M-$27.7M-$21.9M
Pre-tax income -$155.2M-$208.0M-$338.8M-$84.0M-$65.7M-$80.9M-$78.3M-$44.3M-$27.2M-$21.7M
Income tax $15.0K$51.0K$26.0K$136.0K$141.0K$0$0$0$0$0
Net income -$155.2M-$208.0M-$338.8M-$83.8M-$65.8M-$80.9M-$78.3M-$44.3M-$27.2M-$21.7M
EPS, basic ——13.76-24.86-25.02-1.52————
EPS, diluted ——13.76-24.86-25.02-1.52-2.45-2.13-1.80-2.22
Shares, diluted (wtd. avg.) ——6.9M3.4M2.6M53.4M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $85.7M$89.4M$188.9M$36.4M$17.0M$91.9M$19.3M$22.5M$12.8M$47.7M
Short-term investments $670.8M$513.7M$150.4M$20.8M$78.0M$56.2M$52.7M$52.1M$37.5M$15.8M
Total current assets $777.8M$608.5M$341.5M$62.3M$98.9M$149.8M$74.5M$76.7M$55.0M$66.4M
Property, plant and equipment ——$0$3.2M$4.5M$5.6M$2.4M$1.0M$854.0K$599.0K
Total assets $777.8M$608.5M$341.9M$71.1M$109.9M$161.6M$83.2M$77.7M$56.1M$67.1M
Accounts payable ———$677.0K$3.3M$2.3M$3.2M$663.0K$389.0K$168.0K
Total current liabilities $58.7M$54.1M$32.0M$14.7M$20.1M$16.4M$18.4M$10.2M$5.6M$4.0M
Total liabilities $62.5M$90.7M$73.3M$20.8M$26.0M$21.8M$23.1M$10.3M$5.7M$4.1M
Retained earnings -$1.13B-$972.4M-$764.4M-$425.6M-$341.8M-$276.0M-$195.1M-$116.9M-$72.5M-$45.3M
Total equity $715.2M$517.8M$184.0M$50.3M$83.9M$139.8M$60.1M$67.4M$50.3M$63.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$169.3M-$157.4M-$99.9M-$80.1M-$53.7M-$75.8M-$65.7M-$32.2M-$24.6M-$18.8M
Depreciation and amortisation $0$0$744.0K$1.6M$1.6M$996.0K$418.0K$293.0K$249.0K$132.0K
Stock-based compensation $37.6M$44.8M$25.7M$7.1M$8.0M$6.3M$4.9M$4.3M$2.5M$1.2M
Capital expenditure —$0$0$38.0K$573.0K$4.3M$1.5M$422.0K$619.0K$212.0K
Investing cash flow -$143.5M-$353.3M-$108.4M$57.0M-$22.6M-$7.6M-$1.7M-$15.2M-$22.5M-$12.1M
Financing cash flow $309.0M$410.9M$361.1M$42.7M$1.4M$154.5M$65.7M$57.1M$12.2M$49.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001636282-26-000039.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -300M -200M -100M 0 100M Revenue, FY2016: 4.6M Net income, FY2016: -21.7M Revenue, FY2017: 5.2M Net income, FY2017: -27.2M Revenue, FY2018: 3.9M Net income, FY2018: -44.3M Revenue, FY2019: 0 Net income, FY2019: -78.3M Revenue, FY2020: 0 Net income, FY2020: -80.9M Revenue, FY2021: 18.7M Net income, FY2021: -65.8M Revenue, FY2022: 2.3M Net income, FY2022: -83.8M Revenue, FY2023: 886K Net income, FY2023: -338.8M Revenue, FY2024: 0 Net income, FY2024: -208M Revenue, FY2025: 0 Net income, FY2025: -155.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $4.6M $5.2M $3.9M $0 $0 $18.7M $2.3M $886.0K $0 $0
Gross profit — — — — — — — — — —
Net income -$21.7M -$27.2M -$44.3M -$78.3M -$80.9M -$65.8M -$83.8M -$338.8M -$208.0M -$155.2M

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%